Published on
May 26, 2023
- 12:20 GMT
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals and around 900 people diagnosed worldwide.1,2 FOP …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
